< content="width=device-width, initial-scale=1.0"> Dr. Terrence Bjordahl Secures Top Funding for Research on GLP-1 Drugs in ESKD Patients | Internal Medicine | U of U School of Medicine
Skip to main content

Dr. Terrence Bjordahl Secures Top Funding for Research on GLP-1 Drugs in ESKD Patients

Dr. Terrence Bjordahl Awarded Major Grant for GLP-1 Research

Terrence Bjordahl, MD, Associate Professor in the Division of Nephrology at the University of Utah, has been awarded significant funding for his pioneering research project on the impact of GLP-1 drugs on end-stage kidney disease (ESKD) patients. His project, titled "Impact of GLP-1 Drugs on Mortality, Hospitalization, Cardiovascular Outcomes, and Transplant in ESKD Patients," was selected by the DaVita Clinical Research team after receiving the highest number of votes from 324 peers. 

Terrence Bjordahl

Dr. Bjordahl's research aims to explore the potential benefits of GLP-1 drugs—commonly used in diabetes treatment—on patients with ESKD. The study will investigate how these drugs may influence mortality rates, hospitalization frequencies, cardiovascular outcomes, and the likelihood of kidney transplants among this vulnerable patient population.

Dr. Bjordahl's medical journey began at The Ohio State University School of Medicine, where he earned his medical degree in 2001. He then completed his Internal Medicine Residency at the University of Utah School of Medicine in 2004, followed by a Nephrology Fellowship at the same institution in 2007. His dedication to the field led him to join the University of Utah's faculty as an Assistant Professor in the Division of Nephrology.

Dr. Bjordahl serves as the Medical Director of the University of Utah's West Valley Dialysis Center and co-director of Wasatch Kidney Specialists. His leadership and commitment to advancing nephrology are well recognized, and this latest achievement further solidifies his reputation as a leading expert in the field.

The funding from DaVita Clinical Research will enable Dr. Bjordahl and his team to conduct this vital research, potentially paving the way for new treatment protocols that significantly improve outcomes for ESKD patients. The nephrology community eagerly anticipates the findings of this study, which could have far-reaching implications for patient care and treatment strategies.

Dr. Bjordahl's success in securing this competitive funding underscores his innovative approach to nephrology and his commitment to improving patient outcomes. As he embarks on this new research endeavor, his work promises to contribute valuable insights into kidney disease and patient care.